IBA Molecular and Mallinckrodt Nuclear Medicine LLC to create a new, world-class radiopharmaceutical company: Curium

PARIS and ST LOUIS, April 6, 2017 /PRNewswire/ -- "Today, I am excited to announce the uniting of IBA Molecular and Mallinckrodt Nuclear Medicine LLC to create Curium - a world-class provider in nuclear imaging," says Renaud Dehareng, CEO of Curium.

Renaud Dehareng continued by saying, "Our new company has over 100 years of combined experience in the nuclear industry, Curium has a singular focus - to develop, manufacture and supply SPECT, PET, and therapeutic radiopharmaceuticals to our customers around the globe. We have the largest, vertically integrated radiopharmaceutical manufacturing network in the industry. We will use our scale, global reach, manufacturing footprint and an unrivaled logistics and distribution network to deliver superior service that our customers can rely upon every day."

This new entity delivers diagnostic and therapeutic solutions to over 14 million people from a global network of 21 manufacturing centers comprised of 1 Molybdenum facility, 3 large SPECT facilities, and close to 40 PET and SPECT radiopharmacies. Our customer base counts over 6,000 public and private hospitals, radiopharmacies and imaging centers in over 70 countries. Curium customers can expect best-in-class products, exceptional service reliability, a large and diverse product portfolio, a relentless pursuit of stable isotope supply, and a commitment to develop and launch new products.

Speaking on behalf of CapVest, the owner of Curium, Kate Briant, CapVest Partner and Chairman of the Board said, "We are excited to launch this dynamic new brand in the marketplace. We believe the expertise, size and scale, and proven track record of the united companies will provide future growth opportunities in this attractive segment."

The Curium name emphasizes two aspects that are critical to us:

1. It recalls the pioneering spirit and radiation research performed by Marie and Pierre Curie. We want to be a catalyst of nuclear medicine industry growth and support increasing its role in global healthcare.
2. It clearly states our focus on nuclear medicine. We will continue to focus our resources and investments to contribute to our great industry.

Visually, our identity conveys a sense of continuity and advancement along the patient care continuum. Our brand tagline, Life Forward, sums up our commitment to our customers and the industry we serve by enhancing the quality of health outcomes through patient care, life-saving diagnostics and treatment. "We feel this uniquely positions the expanded business, as we build our second century of progress," says Dehareng.

For additional information on Curium, visit our website at curiumpharma.com

Media Contacts:
Janet Ryan
Visintine & Ryan Public Relations
+1-314-822-8860 or +1-314-614-7408
janet@visintineandryan.com

Priscilla Visintine
Visintine & Ryan Public Relations
+1-314-422-5646
priscilla@visintineandryan.com

Logo - http://mma.prnewswire.com/media/487203/Curium_Logo.jpg